The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $17.71 in the prior trading day, Kyverna Therapeutics Inc. (NASDAQ: KYTX) closed at $15.94, down -9.99%. In other words, the price has decreased by -$9.99 from its previous closing price. On the day, 0.59 million shares were traded. KYTX stock price reached its highest trading level at $17.47 during the session, while it also had its lowest trading level at $15.72.
Ratios:
Our goal is to gain a better understanding of KYTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.05 and its Current Ratio is at 3.05. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on March 04, 2024, initiated with a Overweight rating and assigned the stock a target price of $44.
On March 04, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.
On March 04, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $48.Leerink Partners initiated its Outperform rating on March 04, 2024, with a $48 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 12 ’24 when GILEAD SCIENCES, INC. bought 910,000 shares for $22.00 per share. The transaction valued at 20,020,000 led to the insider holds 4,126,119 shares of the business.
Northpond Ventures III GP, LLC bought 450,000 shares of KYTX for $9,900,000 on Feb 12 ’24. The Former 10% Owner now owns 450,000 shares after completing the transaction at $22.00 per share. On Feb 12 ’24, another insider, Bain Capital Life Sciences Inv, who serves as the 10% Owner of the company, bought 450,000 shares for $22.00 each. As a result, the insider paid 9,900,000 and bolstered with 3,163,868 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYTX now has a Market Capitalization of 687256256 and an Enterprise Value of 819366976.
Stock Price History:
Over the past 52 weeks, KYTX has reached a high of $35.06, while it has fallen to a 52-week low of $17.23. The 50-Day Moving Average of the stock is -37.58%, while the 200-Day Moving Average is calculated to be -38.20%.
Shares Statistics:
The stock has traded on average 488.01K shares per day over the past 3-months and 353790 shares per day over the last 10 days, according to various share statistics. A total of 43.12M shares are outstanding, with a floating share count of 30.35M. Insiders hold about 29.61% of the company’s shares, while institutions hold 3.27% stake in the company. Shares short for KYTX as of 1713139200 were 1555465 with a Short Ratio of 3.19, compared to 1710460800 on 1005011. Therefore, it implies a Short% of Shares Outstanding of 1555465 and a Short% of Float of 6.529999999999999.
Earnings Estimates
A comprehensive evaluation of Kyverna Therapeutics Inc. (KYTX) is underway, with the input of 4 analysts contributing to its current rating.On average, analysts expect EPS of -$0.84 for the current quarter, with a high estimate of -$0.64 and a low estimate of -$1.2, while EPS last year was -$26.86. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.66 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$3.11 and -$3.48 for the fiscal current year, implying an average EPS of -$3.27. EPS for the following year is -$4.0, with 4.0 analysts recommending between -$3.5 and -$4.41.
